Clinical trials: B-Cell Acute Lymphoblastic Leukaemia
Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
The treatment of adult B-cell acute lymphoblastic leukaemia (ALL) has progressed considerably in the past 3 decades, particularly due to intensification of chemotherapies, improved supportive care and the incorporation of stem…
- Trial name
- MARALL (NCT01279707)
- Testing
- humanised monoclonal antibody, veltuzumab, humanised monoclonal antibody epratuzumab, humanised monoclonal antibodies veltuzumab and epratuzumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- Queen Mary University of London
Osteonecrosis, Acute Lymphoblastic Leukaemia
Osteonecroses in Pediatric Patients With ALL
Nowadays approximately 80% of children and adolescents with acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) can be cured and become long-term survivors.
- Conditions
- Osteonecrosis, Acute Lymphoblastic Leukaemia, Lymphoblastic Lymphoma
- Trial name
- OPAL (NCT01619124)
- Where
- 25 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immu
Acute Lymphoblastic Leukaemia
A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia
Asparaginase is an important drug i the treatment of childhood leukaemia. The aim of this project is to study the pharmacokinetics, pharmacodynamics and antibody development and hypersensitivity reactions during prolonged…
- Trial name
- NCT01272440
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Aarhus University Hospital
Acute Lymphoblastic Leukaemia
Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia
This is an assessment of efficacy and safety of three different doses of pegylated recombinant asparaginase (PEG-rASNase) in comparison to Oncaspar® during treatment of adults with de novo acute lymphoblastic leukaemia (ALL).
- Trial name
- NCT01251809
- Testing
- Oncaspar, PEG-rASNase
- Where
- 30 sites in Germany
- Volunteers
- 56 people
- Sponsor
- medac GmbH
Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics and safety of different doses of intravenous and oral Forodesine in children with relapsed or refractory T-cell or B-cell precursor Acute…
- Conditions
- Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia, T-cell Non-Hodgkin's Lymphoma
- Trial name
- BCX1777-108 (NCT00742495)
- Testing
- Forodesine
- Where
- 6 sites in Austria, Czechia and 4 more
- Volunteers
- 2 people
- Sponsor
- Mundipharma Research Limited